Oral Therapies Seize the Spotlight in MS
Stellar third quarter earnings reported last week by Biogen Idec Inc., including another home run for the company with Tecfidera (dimethyl fumarate), put a spotlight on the promising pipeline of next-generation multiple sclerosis (MS) drugs. Weston, Mass.-based Biogen is smack in the middle of that hunt. In addition to its four commercial MS products – Ampyra/Fampyra (dalfampridine), Avonex (interferon beta-1a), Tysabri (natalizumab) and Tecfidera – the company has two MS drugs in Phase III development: Plegridy (peginterferon beta-1a) and anti-IL2 antibody daclizumab, which is partnered with Abbvie Inc., of Chicago.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter